To include your compound in the COVID-19 Resource Center, submit it here.

Akebia's vadadustat meets in Phase II for non-dialysis-dependent CKD

Akebia Therapeutics Inc. (NASDAQ:AKBA) said oral vadadustat met the primary endpoint of improving mean hemoglobin levels in a Phase II trial to treat anemia in non-dialysis-dependent patients with chronic kidney disease (CKD). Top-line data from the double-blind, Japanese trial in 51 patients showed

Read the full 434 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE